Novartis May 5, 2026 Celcuity’s gedatolisib beats Novartis drug in Phase III test - The Pharma Letter
Novartis May 4, 2026 After March cuts, Novartis trims another 60 roles at US headquarters - Fierce Pharma
Novartis May 4, 2026 Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3 breast cancer study - Fierce Biotech
Novartis Apr 30, 2026 Novartis to build Morrisville pharma facility as part of $23 billion push - CBS 17
Novartis Apr 30, 2026 Novartis rounds out $23B US investment push with plans for North Carolina API plant - Fierce Pharma
Novartis Apr 30, 2026 Novartis Reshapes Growth With Biotech Deals And AI Powered R&D Push - Yahoo Finance
Novartis Apr 29, 2026 Novartis, PTC push Huntington’s drug into Phase 3, mum on accelerated approval - BioSpace
Novartis Apr 28, 2026 Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies - Fierce Pharma
Novartis Apr 28, 2026 Novartis’ sales dip as generics pressure intensifies, radioequivalents loom - BioSpace
Novartis Apr 28, 2026 Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months' - CNBC
Novartis Apr 28, 2026 Novartis CEO ‘continuing to evaluate’ in vivo CAR-Ts, but no deals in the works - Fierce Biotech
Novartis Apr 27, 2026 Biopharma bites: 'Green shoots' for UK's biotech sector, Ligand buys XOMA and more from AstraZeneca, Novartis - FirstWord Pharma
FierceBiotech Apr 22, 2026 Novartis narrows focus for anticoagulant after failure to best Eliquis in phase 3 trial
FierceBiotech Apr 15, 2026 Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen